202 related articles for article (PubMed ID: 8113841)
1. Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation.
Ghalie R; Richman CM; Adler SS; Cobleigh MA; Korenblit AD; Manson SD; McLeod BC; Taylor SG; Valentino LA; Wolter J
J Clin Oncol; 1994 Feb; 12(2):342-6. PubMed ID: 8113841
[TBL] [Abstract][Full Text] [Related]
2. Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy.
Mundt AJ; Sibley GS; Williams S; Rubin SJ; Heimann R; Halpern H; Weichselbaum RR
Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):151-60. PubMed ID: 8083108
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer.
Gisselbrecht C; Extra JM; Lotz JP; Devaux Y; Janvier M; Peny AM; Guillevin L; Bremond D; Delain M; Herbrecht R; Lepage E; Maraninchi D
Bone Marrow Transplant; 1996 Nov; 18(5):857-63. PubMed ID: 8932837
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.
Antman K; Ayash L; Elias A; Wheeler C; Hunt M; Eder JP; Teicher BA; Critchlow J; Bibbo J; Schnipper LE
J Clin Oncol; 1992 Jan; 10(1):102-10. PubMed ID: 1727912
[TBL] [Abstract][Full Text] [Related]
5. Patterns of failure following bone marrow transplantation for metastatic breast cancer: the role of consolidative local therapy.
Shah AB; Hartsell WF; Ghalie R; Kaizer H
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1433-8. PubMed ID: 7635784
[TBL] [Abstract][Full Text] [Related]
6. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
Ayash LJ; Elias A; Wheeler C; Reich E; Schwartz G; Mazanet R; Tepler I; Warren D; Lynch C; Gonin R
J Clin Oncol; 1994 Jan; 12(1):37-44. PubMed ID: 7505807
[TBL] [Abstract][Full Text] [Related]
7. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.
Peters WP; Shpall EJ; Jones RB; Olsen GA; Bast RC; Gockerman JP; Moore JO
J Clin Oncol; 1988 Sep; 6(9):1368-76. PubMed ID: 3047332
[TBL] [Abstract][Full Text] [Related]
8. Tandem autotransplantation for the treatment of metastatic breast cancer.
Broun ER; Sridhara R; Sledge GW; Loesch D; Kneebone PH; Hanna M; Hromas R; Cornetta K; Einhorn LH
J Clin Oncol; 1995 Aug; 13(8):2050-5. PubMed ID: 7636548
[TBL] [Abstract][Full Text] [Related]
9. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.
Antman K; Ayash L; Elias A; Wheeler C; Schwartz G; Mazanet R; Tepler I; Schnipper LE; Frei E
J Natl Cancer Inst Monogr; 1994; (16):91-4. PubMed ID: 7528031
[TBL] [Abstract][Full Text] [Related]
10. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer.
Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Sniecinski I
Cancer; 1994 Jan; 73(1):125-34. PubMed ID: 7903906
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant.
Myers SE; Mick R; Williams SF
Bone Marrow Transplant; 1994 Apr; 13(4):449-54. PubMed ID: 8019470
[TBL] [Abstract][Full Text] [Related]
12. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer.
Demirer T; Buckner CD; Appelbaum FR; Clift R; Storb R; Myerson D; Lilleby K; Rowley S; Bensinger WI
Bone Marrow Transplant; 1996 May; 17(5):769-74. PubMed ID: 8733696
[TBL] [Abstract][Full Text] [Related]
13. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin.
Ayash LJ; Elias A; Schwartz G; Wheeler C; Ibrahim J; Teicher BA; Reich E; Warren D; Lynch C; Richardson P; Schnipper L; Frei E; Antman K
J Clin Oncol; 1996 Nov; 14(11):2984-92. PubMed ID: 8918496
[TBL] [Abstract][Full Text] [Related]
14. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
15. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.
Eder JP; Antman K; Peters W; Henner WD; Elias A; Shea T; Schryber S; Andersen J; Come S; Schnipper L
J Clin Oncol; 1986 Nov; 4(11):1592-7. PubMed ID: 3534155
[TBL] [Abstract][Full Text] [Related]
16. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W
Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.
Meisenberg BR; Ross M; Vredenburgh JJ; Jones R; Shpall EJ; Seigler HF; Coniglio DM; Wu K; Peters WP
J Natl Cancer Inst; 1993 Jul; 85(13):1080-5. PubMed ID: 8515495
[TBL] [Abstract][Full Text] [Related]
19. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
Antman K; Eder JP; Elias A; Shea T; Peters WP; Andersen J; Schryber S; Henner WD; Finberg R; Wilmore D
Cancer Treat Rep; 1987 Feb; 71(2):119-25. PubMed ID: 3542208
[TBL] [Abstract][Full Text] [Related]
20. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.
Holland HK; Dix SP; Geller RB; Devine SM; Heffner LT; Connaghan DG; Hillyer CD; Hughes LL; Miller RL; Moore MR; Winton EF; Wingard JR
J Clin Oncol; 1996 Apr; 14(4):1156-64. PubMed ID: 8648370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]